Lumykras Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

lumykras

amgen europe bv - sotorasib - karcinóm, pľúc bez malých buniek - antineoplastické činidlá - lumykras as monotherapy is indicated for the treatment of adults with advanced non-small cell lung cancer (nsclc) with kras g12c mutation and who have progressed after at least one prior line of systemic therapy.

Dasatinib Accordpharma Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

dasatinib accordpharma

accord healthcare s.l.u. - dasatinib - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antineoplastické činidlá - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Pyrukynd Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

pyrukynd

agios netherlands b.v. - mitapivat sulfate - genetic diseases, inborn; anemia, hemolytic - other hematological agents - pyrukynd is indicated for the treatment of pyruvate kinase deficiency (pk deficiency) in adult patients (see section 4.

SPASMED 15 Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

spasmed 15

pro.med.cs praha a.s., Česká republika - trospium - 73 - spasmolytica

SPASMED 30 mg Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

spasmed 30 mg

pro.med.cs praha a.s., Česká republika - trospium - 73 - spasmolytica

Angiox Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

angiox

the medicines company uk ltd - bivalirudin - akútny koronárny syndróm - antitrombotické činidlá - angiox je uvedené ako anticoagulant u dospelých pacientov podstupujúcich perkutánnej koronárnej intervencii (pci), vrátane pacientov s st-segmentu-výška infarktu myokardu (stemi) prechádza primárnou pci. angiox je tiež indikovaný na liečbu dospelých pacientov s nestabilnou angina pectoris / non-st-segmentu-výška infarktu myokardu (ua / nstemi) plánované pre naliehavé alebo včasná intervencia. angiox by mali byť spravované s aspirín a klopidogrel.

Edurant Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

edurant

janssen-cilag international n.v.    - rilpivirín hydrochlorid - hiv infekcie - antivirotiká na systémové použitie - edurant, v kombinácii s inými antiretrovírusovými liekmi, je indikovaný na liečbu vírusu ľudskej imunodeficiencie typu 1 (hiv‑1) infekcia u antiretrovírusová treatment‑naïve 12 rokov a starších s vírusovej záťaže ≤ 100 000 hiv‑1 nedetekovateľnej. rovnako ako u iných antiretrovirálnej liekov, genotypic odpor testovanie by sa malo riadiť použitie edurant.

FENOLAX Σλοβακία - Σλοβακικά - ŠÚKL (Štátny ústav pre kontrolu liečiv)

fenolax

bausch + lomb ireland limited, Írsko - bisakodyl - 61 - laxantia

Stelfonta Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

stelfonta

qbiotics netherlands b.v. - tigilanol tiglate - tigilanol tiglate - psy - pri liečbe non-resectable, non-metastatické (ktorÍ inscenácia) podkožného žírnych buniek nádorov sa nachádza v distálnej koleno alebo päty, a non-resectable, non metastatickým kožných žírnych buniek nádorov u psov.

Calquence Ευρωπαϊκή Ένωση - Σλοβακικά - EMA (European Medicines Agency)

calquence

astrazeneca ab - acalabrutinib - leukémia, lymfocytárna, chronická, b-bunka - antineoplastic agents, protein kinase inhibitors, - calquence as monotherapy or in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll). calquence as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukaemia (cll) who have received at least one prior therapy.